249.8: SARS-coV-2 Antibody Response by mRNA Vaccine Platform in Incrementally Immunosuppressed Patients
Jonathan Mitchell(AstraZeneca (Australia)), Allan B. Massie(Johns Hopkins University), Caoilfhionn M Connolly, William A. Werbel(Johns Hopkins University), Jennifer L. Alejo(Johns Hopkins University), Dorry L. Segev(New York University), Teresa Po‐Yu Chiang(Johns Hopkins University)
Cited by 0
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
|JAMA|2021|536
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
|New England Journal of Medicine|2015|450